A phase 2 trial of GR1014-CG 2.4% in advanced solid tumours, run by Graegis Pharmaceuticals Ltd, active and no longer recruiting.
A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer is a phase 2 interventional study registered as NCT07192588 by Graegis Pharmaceuticals Ltd, with 273 participants enrolled, started 2024-07-26 and due to reach its primary completion in 2026-09-30. Interventions recorded: GR1014-CG 2.4%, Vehicle Gel, Radiation Therapy and GR1014-CG 4.7%.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.